GGrantIndex
← Leaderboards

Shabaana A. Khader

University Of Chicago

Google Scholar ↗PubMed ↗ORCID ↗
$24,868,402
Attributed
$40,997,409
Total exposure
14
Grants
13
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5M · FY2007–25
$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$40,997,409 · 14

By mechanism

R01$34,129,758 · 7
U01$2,967,748 · 1
R61$1,420,332 · 1
R33$1,067,980 · 1
R21$836,000 · 2
R00$485,591 · 1

Top collaborators

Most similar at University Of Chicago

Same institution · by research overlap

Others in their field

Top investigators on “Mediating”

Research focus

MediatingTuberculosisMycobacterium TuberculosisVaccinesLungTuberculosis VaccinesImmunityResponseMouse ModelCellsPulmonary TuberculosisCytokineMycobacterium BovisImmune ResponseT-LymphocyteNonhuman PrimateDesignProductionCessation Of LifeVaccine-Induced ImmunityPreventResistant StrainMacrophageGenes

Grant awards (63)

Role of Inducible Bronchus Associated Lymphoid Tissue in Latent Tuberculosis$1,368,144
R01 · FY2025 · AI · contact PI
Mechanisms of efficient control of Mycobacterium tuberculosis in the lungs prior to granuloma$1,231,164
R01 · FY2025 · AI
Development of a novel adjuvanted Th1- and Th17-inducing subunit TB Vaccine$1,067,980
R33 · FY2025 · AI · contact PI
Targeting trained immunity and Th1/Th17 axis with combination adjuvants$600,000
U01 · FY2025 · AI · contact PI
Role of IL-17 in Protective Vaccine-induced Immune Responses Against Tuberculosis$582,022
R01 · FY2025 · HL · contact PI
Role of Inducible Bronchus Associated Lymphoid Tissue in Latent Tuberculosis$1,368,144
R01 · FY2024 · AI · contact PI
Mechanisms of efficient control of Mycobacterium tuberculosis in the lungs prior to granuloma$1,091,124
R01 · FY2024 · AI
Understanding the functional role of Myeloid Derived Suppressor cells in tuberculosis$881,854
R01 · FY2024 · AI · contact PI
Targeting trained immunity and Th1/Th17 axis with combination adjuvants$600,000
U01 · FY2024 · AI · contact PI
Role of IL-17 in Protective Vaccine-induced Immune Responses Against Tuberculosis$570,382
R01 · FY2024 · HL · contact PI
Development of a novel adjuvanted Th1- and Th17-inducing subunit TB Vaccine$472,273
R61 · FY2024 · AI · contact PI
Role of Inducible Bronchus Associated Lymphoid Tissue in Latent Tuberculosis$1,415,724
R01 · FY2023 · AI · contact PI
A Novel Th17-inducing Mucosal Vaccine for Tuberculosis$914,044
R01 · FY2023 · AI · contact PI
Understanding the functional role of Myeloid Derived Suppressor cells in tuberculosis$897,854
R01 · FY2023 · AI · contact PI
Targeting trained immunity and Th1/Th17 axis with combination adjuvants$599,999
U01 · FY2023 · AI · contact PI
Role of IL-17 in Protective Vaccine-induced Immune Responses Against Tuberculosis$582,022
R01 · FY2023 · HL · contact PI
Development of a novel adjuvanted Th1- and Th17-inducing subunit TB Vaccine$480,170
R61 · FY2023 · AI · contact PI
Role of Inducible Bronchus Associated Lymphoid Tissue in Latent Tuberculosis$1,363,070
R01 · FY2022 · AI · contact PI
Understanding the functional role of Myeloid Derived Suppressor cells in tuberculosis$869,240
R01 · FY2022 · AI · contact PI
A Novel Th17-inducing Mucosal Vaccine for Tuberculosis$864,661
R01 · FY2022 · AI · contact PI
Role of IL-17 in Protective Vaccine-induced Immune Responses Against Tuberculosis$567,793
R01 · FY2022 · HL · contact PI
Targeting trained immunity and Th1/Th17 axis with combination adjuvants$567,749
U01 · FY2022 · AI · contact PI
Development of a novel adjuvanted Th1- and Th17-inducing subunit TB Vaccine$467,889
R61 · FY2022 · AI · contact PI
Role of Inducible Bronchus Associated Lymphoid Tissue in Latent Tuberculosis$1,391,820
R01 · FY2021 · AI · contact PI
A Novel Th17-inducing Mucosal Vaccine for Tuberculosis$811,554
R01 · FY2021 · AI · contact PI
Understanding the functional role of Myeloid Derived Suppressor cells in tuberculosis$720,290
R01 · FY2021 · AI · contact PI
The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis$674,402
R01 · FY2021 · AI · contact PI
Targeting trained immunity and Th1/Th17 axis with combination adjuvants$600,000
U01 · FY2021 · AI · contact PI
The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis$241,329
R01 · FY2021 · AI · contact PI
A Novel Th17-inducing Mucosal Vaccine for Tuberculosis$799,386
R01 · FY2020 · AI · contact PI
Understanding the functional role of Myeloid Derived Suppressor cells in tuberculosis$734,665
R01 · FY2020 · AI · contact PI
The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis$674,402
R01 · FY2020 · AI · contact PI
The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis$358,637
R01 · FY2020 · AI · contact PI
The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis$117,308
R01 · FY2020 · AI · contact PI
ROLE OF INDUCIBLE BRONCHUS ASSOCIATED LYMPHOID TISSUE IN LATENT TUBERCULOSIS$800,095
R01 · FY2019 · AI · contact PI
The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis$674,402
R01 · FY2019 · AI · contact PI
COMMON IMMUNE CORRELATES OF RISK OF TB DISEASE IN ANIMAL MODELS AND HUMANS$668,570
R01 · FY2019 · AI · contact PI
ROLE OF IL-17 IN PROTECTIVE VACCINE-INDUCED IMMUNE RESPONSES AGAINST TUBERCULOSIS$408,644
R01 · FY2019 · HL · contact PI
The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis$976,790
R01 · FY2018 · AI · contact PI
ROLE OF INDUCIBLE BRONCHUS ASSOCIATED LYMPHOID TISSUE IN LATENT TUBERCULOSIS$800,058
R01 · FY2018 · AI · contact PI
COMMON IMMUNE CORRELATES OF RISK OF TB DISEASE IN ANIMAL MODELS AND HUMANS$726,447
R01 · FY2018 · AI · contact PI
ROLE OF IL-17 IN PROTECTIVE VACCINE-INDUCED IMMUNE RESPONSES AGAINST TUBERCULOSIS$417,072
R01 · FY2018 · HL · contact PI
ROLE OF INDUCIBLE BRONCHUS ASSOCIATED LYMPHOID TISSUE IN LATENT TUBERCULOSIS$877,406
R01 · FY2017 · AI · contact PI
COMMON IMMUNE CORRELATES OF RISK OF TB DISEASE IN ANIMAL MODELS AND HUMANS$734,575
R01 · FY2017 · AI · contact PI
The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis$712,802
R01 · FY2017 · AI · contact PI
ROLE OF IL-17 IN PROTECTIVE VACCINE-INDUCED IMMUNE RESPONSES AGAINST TUBERCULOSIS$426,417
R01 · FY2017 · HL · contact PI
MODIFYING THE LUNG TO INDUCE STERILE VACCINE-INDUCED PROTECTION AGAINST MTB INFECTION$228,750
R21 · FY2017 · AI · contact PI
ROLE OF INDUCIBLE BRONCHUS ASSOCIATED LYMPHOID TISSUE IN LATENT TUBERCULOSIS$895,155
R01 · FY2016 · AI · contact PI
COMMON IMMUNE CORRELATES OF RISK OF TB DISEASE IN ANIMAL MODELS AND HUMANS$746,671
R01 · FY2016 · AI · contact PI
ROLE OF IL-17 IN PROTECTIVE VACCINE-INDUCED IMMUNE RESPONSES AGAINST TUBERCULOSIS$467,040
R01 · FY2016 · HL · contact PI
MODIFYING THE LUNG TO INDUCE STERILE VACCINE-INDUCED PROTECTION AGAINST MTB INFECTION$190,625
R21 · FY2016 · AI · contact PI
ROLE OF INDUCIBLE BRONCHUS ASSOCIATED LYMPHOID TISSUE IN LATENT TUBERCULOSIS$15,462
R01 · FY2016 · AI · contact PI
ROLE OF INDUCIBLE BRONCHUS ASSOCIATED LYMPHOID TISSUE IN LATENT TUBERCULOSIS$826,347
R01 · FY2015 · AI · contact PI
ROLE OF IL-17 IN PROTECTIVE VACCINE-INDUCED IMMUNE RESPONSES AGAINST TUBERCULOSIS$374,300
R01 · FY2015 · HL · contact PI
ROLE OF IL-17 IN PROTECTIVE VACCINE-INDUCED IMMUNE RESPONSES AGAINST TUBERCULOSIS$372,400
R01 · FY2014 · HL · contact PI
Role of IL-17 in protective vaccine-induced immune responses against tuberculosis$360,570
R01 · FY2013 · HL · contact PI
Role of IL-17 in protective vaccine-induced immune responses against tuberculosis$378,750
R01 · FY2012 · HL · contact PI
Role of IL-17 in protective vaccine-induced immune responses against tuberculosis$378,750
R01 · FY2011 · HL · contact PI
Impact of mucosal immunization on generation of protective lung-resident IL-17 pr$189,375
R21 · FY2010 · AI · contact PI
Novel IL-17 producing memory cells are key to vaccine-based immunity in the lung$236,591
R00 · FY2009 · AI · contact PI
Impact of mucosal immunization on generation of protective lung-resident IL-17 pr$227,250
R21 · FY2009 · AI · contact PI
Novel IL-17 producing memory cells are key to vaccine-based immunity in the lung$249,000
R00 · FY2008 · AI · contact PI
Novel IL-17 producing memory cells are key to vaccine-based immunity in the lung$90,000
K99 · FY2007 · AI · contact PI